139 related articles for article (PubMed ID: 36099124)
21. Prominent hypereosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer.
Takeda H; Nishikawa H; Tsumura T; Sekikawa A; Maruo T; Okabe Y; Kimura T; Wakasa T; Osaki Y
Intern Med; 2014; 53(6):563-9. PubMed ID: 24633025
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E
Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648
[TBL] [Abstract][Full Text] [Related]
23. Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.
Muto O; Munakata M; Yamagata K; Masuda A; Kotanagi K; Kichiraku T; Satoyoshi R; Kudoh K; Sawada T; Miyazawa H; Ouchi S; Kotanagi H; Sakata Y
Gan To Kagaku Ryoho; 2017 Oct; 44(10):867-869. PubMed ID: 29066681
[TBL] [Abstract][Full Text] [Related]
24. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
De Vita F; Orditura M; Matano E; Bianco R; Carlomagno C; Infusino S; Damiano V; Simeone E; Diadema MR; Lieto E; Castellano P; Pepe S; De Placido S; Galizia G; Di Martino N; Ciardiello F; Catalano G; Bianco AR
Br J Cancer; 2005 May; 92(9):1644-9. PubMed ID: 15856038
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study.
Nardi M; Azzarello D; Maisano R; Del Medico P; Giannicola R; Raffaele M; Zavettieri M; Costarella S; Falzea A
J Chemother; 2007 Feb; 19(1):85-9. PubMed ID: 17309856
[TBL] [Abstract][Full Text] [Related]
28. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
29. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
31. Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).
Wang X; Wang Y; Qiu M; Li Q; Li ZP; He B; Xu F; Shen YL; Gou HF; Yang Y; Cao D; Yi C; Liu JY; Luo DY; Liao ZY; Bi F
Med Oncol; 2011 Dec; 28 Suppl 1():S274-9. PubMed ID: 21116880
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
[TBL] [Abstract][Full Text] [Related]
33. [A Long‒Term Survival Case of Gastric Cancer with Disseminated Intravascular Coagulation due to Myelocarcinomatosis Treated with S‒1 plus Oxaliplatin Therapy].
Morita R; Ishikawa T; Sawai Y; Kajiwara M; Asaeda K; Kobayashi R; Miyazaki H; Doi T; Inoue K; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Naito Y; Itoh Y
Gan To Kagaku Ryoho; 2021 May; 48(5):731-734. PubMed ID: 34006725
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Ferrand FR; Gontier E; Guymar S; Fagot T; Ceccaldi B; Malfuson JV; de Revel T
Onkologie; 2012; 35(3):118-20. PubMed ID: 22414976
[TBL] [Abstract][Full Text] [Related]
36. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
Keam B; Im SA; Han SW; Ham HS; Kim MA; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Heo DS; Kim WH; Bang YJ
BMC Cancer; 2008 May; 8():148. PubMed ID: 18505590
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis.
Kang SH; Min SH; Kim JW; Lee E; Park SW; Lee S; Oh HJ; Park YS; Lee YJ; Kim JW; Ahn SH; Suh YS; Lee KW; Lee HS; Kim HH
Ann Surg Oncol; 2022 Aug; 29(8):5084-5091. PubMed ID: 35322307
[TBL] [Abstract][Full Text] [Related]
39. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Kim YJ; Goh PG; Kim ES; Lee SY; Moon HS; Lee ES; Sung JK; Kim SH; Lee BS; Jeong HY
Korean J Gastroenterol; 2011 Dec; 58(6):311-7. PubMed ID: 22198228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
